Natrunix Safety PK Study in Healthy Volunteers

Phase 1

• Conditions: Pharmacokinetics
• Interventions: Biological: Placebo; Biological: NatrunixTM

• Registration Number: NCT05099510
• Lead Sponsor: XBiotech, Inc.

Brief Summary

This trial will be a Phase I Open Label, Placebo-controlled Dose Escalation Study to Evaluate Safety and Pharmacokinetics of Natrunix via Subcutaneous Injection in Healthy Subjects. The target enrollment is 8 healthy subjects per cohort (including six for Natrunix and two for placebo). Three cohorts for a total of 24 healthy volunteers.

Detailed Description

Study Title: A Phase I Open Label, Placebo-controlled Dose Escalation Study to Evaluate Safety and Pharmacokinetics of Natrunix via Subcutaneous Injection in Healthy Subjects.

Sponsor: XBiotech USA, Inc.

Study Chair: Neha Reshamwala, MD

Number of Planned Subjects: Eight healthy subjects per cohort (including six for Natrunix and two for placebo). Three cohorts for a total of 24 healthy volunteers.

Approximate Duration: Approximately 38 days for each subject which includes a screening period of up to 10 days followed by one subcutaneous dose of Natrunix, and then evaluation over 28 days. Blood will be sampled at various time points for blood chemistry, hematological analysis and Natrunix serum/plasma concentrations.

Study Timeline

• Study First Submitted: 2021-09-16
• Study First Submitted QC: 2021-10-18
• Study First Posted: 2021-10-29
• Study Start: 2022-01-19
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-07
• Last Update Posted: 2022-02-24
• Primary Completion: 2022-05-01
• Study Completion: 2022-06-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Age: ≥ 18

2. Adequate bone marrow function defined as:

   • absolute neutrophil count (neutrophil and bands) of ≥ 1,500/mm3 (≥ 1.5 x 109/L)
   • platelet count > 150,000/mm3
   • hemoglobin of ≥ 10 g/dL

3. Adequate renal function, defined by serum creatinine ≤ 1.5 x lab ULN.

4. Adequate hepatic function defined as:

5. serum albumin ≥ 3.0 g/dL

6. total bilirubin ≤ 1.5 times lab ULN.

7. alanine aminotransferase (ALT) ≤ 2.0 times lab ULN.

8. aspartate aminotransferase (AST) ≤ 2.0 times lab ULN

9. For WOCBP, a negative pregnancy test at screening. For subjects with reproductive potential, willingness to use one method of contraception of high efficacy during the entire study period. These methods can include but not limited to hormonal contraceptives, intrauterine devices, condoms, diaphragms etc. Women of non-childbearing potential include those considered to have a medical history that indicates that pregnancy is not a reasonable risk, including post-menopausal women and those with a history of hysterectomy or surgically sterilized.

10. If the participant is a male participating in this clinical research study, the subject should not get a sexual partner pregnant during participation in this research study as the effect of the study drug on sperm is not known. The male contraception methods can include but not limited to mechanical methods (abstinence, withdrawal, non-vaginal intercourse) or contemporary methods comprising condoms and vasectomy.

11. Signed and dated Institutional Review Board (IRB) approved informed consent before any protocol-specific screening procedures are performed.

Read More

Exclusion Criteria

1. Treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer).

2. Uncontrolled or significant cardiovascular disease, including:

   • A myocardial infarction within the past 6 months.
   • Uncontrolled angina within the past 3 months.
   • Congestive heart failure within the past 3 months, defined as New York Heart Association (NYHA) Class II or higher.
   • Uncontrolled hypertension (blood pressure >160 mm Hg systolic or >100 mm Hg diastolic).

3. Dementia or altered mental status that would prohibit the understanding or rendering of informed consent.

4. Treatment with immunosuppressant agents, including corticosteroids or cyclosporine within the last 4 weeks.

5. Serious uncontrolled medical disorders, such as uncontrolled diabetes, active peptic ulcer disease, cerebrovascular accident within three months, ongoing congestive heart failure, and any other condition, which in the opinion of the investigator, would put the subject at risk by participating in the trial.

6. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.

7. Abnormal ECG with any clinically significant findings or with QTc > 470 ms.

8. Infection requiring treatment with antibiotics within 3 weeks prior to screening.

9. Infectious disease:

   • Positive HIV, RPR, Hepatitis B or C, TB (QuantiFERON-TB Gold (QFT)/ IGRA)

10. History of immunodeficiency.

11. Female subjects who are pregnant, planning to become pregnant during the course of the study, or breast-feeding.

12. Major surgery within 28 days prior to Day 0.

13. History of progressive multifocal leukoencephalopathy (PML) or other demyelinating disease.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Each participant will receive one single subcutaneous injection of placebo.
NatrunixTM	NatrunixTM	Each participant will receive one single subcutaneous injection of 200 mg (Cohort 1), 400 mg (Cohort 2), or 800 mg (Cohort 3) of NatrunixTM.

Primary Outcome Measures

Name	Time	Method
Number of subjects with treatment related adverse events assessed according to CTCAE v5.0	28 days	Participants will be monitored for acute reactions, blood chemistry and hematology immediately after dosing and at multiple time points up to 28 days. All adverse events will be documented at multiple time points and assessed in terms those possibly, probably and definitely related to test article according to CTCAE v4.0 criteria. Anti-drug antibodies (ADA) will also be evaluated.

Secondary Outcome Measures

Name	Time	Method
Maximum plasma concentration of test article 2) Terminal plasma concentration 3) Plasma half-life 4) Total exposure	28 days	The maximum plasma concentration will be assessed using a proprietary immunoassay to detect circulating NatrunixTM
Terminal plasma concentration	28 days	Terminal plasma concentration will be assessed at 28 days.
Half-life	28 days	Peak and terminal plasma levels will be used in a two compartmental model to assess plasma half-life.
Total exposure	28 days	Area under the curve will be determined based on measured plasma levels over 28 days.

Trial Locations

Locations (1)

BioBehavioral Research of Austin, A Telemed2U Company; 🇺🇸 Austin, Texas, United States